Glykrez-OD 60 Tablet contains Gliclazide 60 mg, a sulfonylurea class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby reducing blood glucose levels. This medication is indicated for patients whose diabetes cannot be controlled by diet and exercise alone. Glykrez-OD 60 is formulated as an oral dispersible tablet, allowing for ease of administration and improved patient compliance. It is typically prescribed once daily, preferably before a meal, to optimize glycemic control. The drug’s extended-release properties help maintain stable plasma concentrations, minimizing the risk of hypoglycemia and enhancing therapeutic efficacy. Patients should be monitored regularly for blood glucose levels and any adverse effects, including hypoglycemia, gastrointestinal disturbances, or allergic reactions. Caution is advised in patients with hepatic or renal impairment, and it should be used under medical supervision in pregnant or lactating women. Glykrez-OD 60 should not be used in type 1 diabetes or diabetic ketoacidosis. Adequate lifestyle modifications, including diet and exercise, should accompany pharmacotherapy for optimal management of hyperglycemia.